中国药业
中國藥業
중국약업
China Pharmaceuticals
2015年
17期
33-34
,共2页
恩替卡韦%吗替麦考酚酯%乙型肝炎病毒相关性肾炎%临床疗效%安全性
恩替卡韋%嗎替麥攷酚酯%乙型肝炎病毒相關性腎炎%臨床療效%安全性
은체잡위%마체맥고분지%을형간염병독상관성신염%림상료효%안전성
entecavir%mycoPhenolate mofetil%hePatitis B virus associated glomerulonePhritis%clinical efficacy%safety
目的：探讨恩替卡韦联合吗替麦考酚酯治疗乙型肝炎病毒相关性肾炎（HBVGN）的临床疗效并评价其安全性。方法选择收治的HBVGN患者58例，随机分为对照组和观察组，各29例。对照组予恩替卡韦联合醋酸泼尼松龙，观察组予恩替卡韦联合吗替麦考酚酯。结果对照组患者治疗总有效率为89.65％，高于对照组的75.86％（ P ＜0.05）。两组患者 HBV－DNA水平较治疗前均明显下降（ P＜0.05），但组间未见显著性差异（ P＞0.05）。治疗后两组患者24 h尿蛋白及血肌酐较前均有明显下降，且观察组下降程度较对照组明显（ P＜0.05）。治疗后两组患者白蛋白较前明显上升，而丙氨酸氨基转移酶及天门冬酸氨基转移酶较前明显下降（ P＜0.05），而治疗后两组上述指标间未见明显差异（ P＞0.05）。两组患者药品不良反应发生率间未见明显差异（ P＞0.05）。结论恩替卡韦联合吗替麦考酚酯治疗HBVGN疗效确切，且安全性良好。
目的：探討恩替卡韋聯閤嗎替麥攷酚酯治療乙型肝炎病毒相關性腎炎（HBVGN）的臨床療效併評價其安全性。方法選擇收治的HBVGN患者58例，隨機分為對照組和觀察組，各29例。對照組予恩替卡韋聯閤醋痠潑尼鬆龍，觀察組予恩替卡韋聯閤嗎替麥攷酚酯。結果對照組患者治療總有效率為89.65％，高于對照組的75.86％（ P ＜0.05）。兩組患者 HBV－DNA水平較治療前均明顯下降（ P＜0.05），但組間未見顯著性差異（ P＞0.05）。治療後兩組患者24 h尿蛋白及血肌酐較前均有明顯下降，且觀察組下降程度較對照組明顯（ P＜0.05）。治療後兩組患者白蛋白較前明顯上升，而丙氨痠氨基轉移酶及天門鼕痠氨基轉移酶較前明顯下降（ P＜0.05），而治療後兩組上述指標間未見明顯差異（ P＞0.05）。兩組患者藥品不良反應髮生率間未見明顯差異（ P＞0.05）。結論恩替卡韋聯閤嗎替麥攷酚酯治療HBVGN療效確切，且安全性良好。
목적：탐토은체잡위연합마체맥고분지치료을형간염병독상관성신염（HBVGN）적림상료효병평개기안전성。방법선택수치적HBVGN환자58례，수궤분위대조조화관찰조，각29례。대조조여은체잡위연합작산발니송룡，관찰조여은체잡위연합마체맥고분지。결과대조조환자치료총유효솔위89.65％，고우대조조적75.86％（ P ＜0.05）。량조환자 HBV－DNA수평교치료전균명현하강（ P＜0.05），단조간미견현저성차이（ P＞0.05）。치료후량조환자24 h뇨단백급혈기항교전균유명현하강，차관찰조하강정도교대조조명현（ P＜0.05）。치료후량조환자백단백교전명현상승，이병안산안기전이매급천문동산안기전이매교전명현하강（ P＜0.05），이치료후량조상술지표간미견명현차이（ P＞0.05）。량조환자약품불량반응발생솔간미견명현차이（ P＞0.05）。결론은체잡위연합마체맥고분지치료HBVGN료효학절，차안전성량호。
Objective To investigate the clinical curative effect of entecavir combined with mycoPhenolate mofetil on hePatitis B virus associated glomerulonePhritis. Methods 58 cases of Patients diagnosed HBVGN were randomly divided in to the control grouP ( n=29 ) and the observation grouP ( n=29 ) ,the control grouP was given a grant for entecavir combined with Prednisolone acetate,the observation grouP received entecavir combined with mycoPhenolate mofetil. Results The total effective rate was 89. 65% in the observation grouP, which was significantly higher than 75. 86% in the control grouP ( P < 0. 05 ) . The HBV-DNA of the two grouPs were significantly lower than before treatment ( P < 0. 05 ) ,but there was no significant difference between the two grouPs ( P > 0. 05 ) . 24 h urine Protein and serum creatinine were significantly decreased in the two grouPs after treatment,and the observation grouP was significantly lower than that in the control grouP ( P < 0. 05 ) . After treatment,the ALB of the two grouPs were significantly higher than before,and ALT and AST were significantly decreased ( P < 0. 05 ) ,but there was no significant difference between the two grouPs ( P > 0. 05 ) . There was no significant difference between the two grouPs in the incidence of adverse drug reactions ( P > 0. 05 ) . Conclusion The efficacy of Entecavir combined with mycoPhenolate mofetil in treating HBVGN is exact with good safety.
